Roundtable Roundup: Challenges of Treating Myelofibrosis
In separate live virtual events, James K. McCloskey II, MD, and Bart L. Scott, MD, polled participants on disease symptoms and bridging therapy options for a patient with primary myelofibrosis (PMF).
CASE SUMMARY
A man aged 62 years presented to his primary care physician (PCP) with symptoms of fatigue, night sweats, and increased bruising .
Medical history: type 2 diabetes, hypercholesterolemia, and hypertension
The PCP noticed lower hemoglobin concentration (11.0-9.5 g/dL) and platelet count (350,000-195,000/μL) from a previous annual physical examination.
Two months post PCP visit, a hematologic oncologist saw him.
Examination findings: spleen 5 cm below left costal margin, fatigue and night sweats worsening, bone pain
Hemoglobin: 9.1 g/dL
Platelet count: 135,000/μL
Bone marrow fibrosis of grade 2/3, with less than 5% bone marrow blasts
Molecular analysis showed a JAK2 V617F mutation with normal karyotype and no additional mutations .
He had a history of squamous cell carcinoma of the skin .
ECOG performance status: 2
Blood: 1% blasts by manual count/flow cytometry
Diagnosis: PMF
Durvalumab Plus Chemotherapy Wins FDA Approval in dMMR Endometrial Cancer
June 14th 2024The FDA has approved a treatment regimen combining durvalumab with carboplatin and paclitaxel, followed by durvalumab monotherapy, for adults with primary advanced or recurrent endometrial cancer that is deficient in mismatch repair.
Read More
Unlocking the Potential of Technology in Community Oncology
In this episode of Targeted Talks, Nini Wu, MD, MBA, shares her insights on the ever-changing world of technology in community oncology.
Listen
